This episode explores the future of the structural heart market, a key growth area in MedTech. We discuss the technological advancements in imaging, catheter tools, and procedural guidance that are shaping the industry. We analyze how leading companies like Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific are moving beyond single implants to create comprehensive procedural ecosystems, and what this means for market leadership by 2026.

- Why is the structural heart market one of MedTech's most attractive growth arenas?

- How are advancements in imaging and catheters changing cardiac procedures?

- What does it mean to own the full "ecosystem" in structural heart therapy?

- Which companies are best positioned to dominate the market by 2026?

- How is the focus shifting from a single device to a complete procedural solution?

- What are the key differences between TAVR and TMVR procedures?

- What role will AI and advanced software play in the future of structural heart interventions?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. We help you develop regulatory strategies, prepare technical dossiers, and act as your local representative in over 30 markets. From market selection to post-market surveillance, our technology-driven solutions ensure efficiency and compliance. Whether you are a startup or a multinational enterprise, Pure Global provides scalable support to bring your innovations to market faster. Contact us at [email protected], visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.